Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: April 29th, 2010 - April 29th, 2011

Target Audience
This activity was developed for physicians, nurses, pharmacists, and other healthcare professionals practicing in a managed care environment.

Learning Objectives
At the completion of this activity participants should be able to:

  • Outline the impact of overactive bladder (OAB) on patients and US healthcare stakeholders, as well as the economic burden on stakeholders, health plans, employers, hospitals, and long-term care facilities
  • Identify and describe the pathophysiology of OAB
  • Discuss guideline-based recommendations for the appropriate assessment and management of OAB
  • Assess the safety and efficacy of current treatment strategies used to diagnose and treat patients with OAB
  • Implement strategies to prevent residual OAB risk and implications in health plan participants


Estimated time to complete this activity: 1 hour

Physician Credit Designation
The University of Cincinnati designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians should only claim credit commensurate with the extent of their participation in this activity.


Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour.


Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-10-020-H01-P

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

Loretta Fala has nothing to disclose.

Peer reviewer Jayshree Shah, RN, APN-C, MSN, BSN, BS, is on the Speaker's Bureau for Bristol-Myers Squibb, Celgene, Merck, and Novartis, and is on the Advisory Board for Bristol-Myers Squibb and Novartis.

The University of Cincinnati, the associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.


Faculty Disclosures
Eric G. Tangalos, MD, FACP, AGSF, CMD, is a consultant to Amgen, Benevia, Novartis, Purdue, and Takeda.

*Content will include non-FDA-approved uses.


The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Trade names used in this supplement are for the learner's reference only. No promotion of or bias toward any product should be inferred.

Last modified: March 21, 2014